Pieris Pharmaceuticals, Inc. (PIRS)
NASDAQ: PIRS · Real-Time Price · USD
17.00
0.00 (0.00%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Pieris Pharmaceuticals Revenue
Pieris Pharmaceuticals had revenue of $20.87M in the twelve months ending June 30, 2024, down -37.15% year-over-year. In the year 2023, Pieris Pharmaceuticals had annual revenue of $42.81M with 65.28% growth.
Revenue (ttm)
$20.87M
Revenue Growth
-37.15%
P/S Ratio
1.02
Revenue / Employee
$417,440
Employees
50
Market Cap
22.44M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 42.81M | 16.91M | 65.28% |
Dec 31, 2022 | 25.90M | -5.52M | -17.56% |
Dec 31, 2021 | 31.42M | 2.10M | 7.14% |
Dec 31, 2020 | 29.32M | -16.96M | -36.64% |
Dec 31, 2019 | 46.28M | 17.18M | 59.03% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Retractable Technologies | 38.25M |
Ekso Bionics Holdings | 17.68M |
Tonix Pharmaceuticals Holding | 12.46M |
Palatin Technologies | 4.49M |
Beyond Air | 1.78M |
Aprea Therapeutics | 1.28M |
PIRS News
- 14 days ago - Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference - GlobeNewsWire
- 26 days ago - Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations - GlobeNewsWire
- 2 months ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders - GlobeNewsWire
- 3 months ago - PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS - Business Wire
- 3 months ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Pieris Pharmaceuticals, Inc. - PRNewsWire
- 3 months ago - Dr. Vince Clinical Research Presents Groundbreaking Webinar on Accelerating Clinical & Drug Development Timelines with AI - Business Wire
- 3 months ago - Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement - Accesswire
- 6 months ago - Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split - Accesswire